FDA Drug Recalls

Recalls / Class II

Class IID-0917-2023

Product

Atropine Sulfate Injection, USP 8 mg per 20 mL (0.4 mg per mL), 20 mL Multiple Dose Vials, Rx only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited Ahmedabad-382 210, India, NDC 16729-512-43.

Brand name
Atropine Sulfate
Generic name
Atropine Sulfate
Active ingredient
Atropine Sulfate
Route
Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous
NDC
16729-512
FDA application
ANDA213424
Affected lot / code info
Lot #: M2210154 Exp. date 06/2025; M2212575 Exp. date 08/2025

Why it was recalled

Presence of Particulate Matter: Particulate matter identified as fiber.

Recalling firm

Firm
Accord Healthcare, Inc.
Manufacturer
Accord Healthcare Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1009 Slater Rd Ste 210B, N/A, Durham, North Carolina 27703-8446

Distribution

Quantity
2348 vials
Distribution pattern
Nationwide within the United States

Timeline

Recall initiated
2023-07-03
FDA classified
2023-07-13
Posted by FDA
2023-07-19
Terminated
2024-10-17
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0917-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.